Smart Blood Analytics Swiss Attains EU-MDR Certification for VIRUS vs. BACTERIA Model: A Game-Changer in Antimicrobial Resistance Battle

ZÜRICH, April 29, 2024 — Smart Blood Analytics Swiss, a leading healthcare technology company, has achieved a significant milestone in the fight against antimicrobial resistance (AMR). The company proudly announces the attainment of EU-MDR (European Medical Device Regulation) certification for its revolutionary VIRUS vs. BACTERIA Clinical Decision Support Software. This innovative medical device promises to revolutionize infectious disease management by accurately distinguishing between viral and bacterial infections, thereby facilitating targeted and effective treatment strategies.

The Global Threat of Antimicrobial Resistance

Antimicrobial resistance poses a formidable challenge to global public health, contributing to millions of deaths annually. Mainly driven by the misuse and overuse of antibiotics, AMR undermines the efficacy of treatments for infectious diseases, escalating healthcare costs and endangering modern medical advancements. The World Health Organization (WHO) underscores the importance of preventing infections, ensuring universal access to quality diagnosis and treatment, and promoting innovation in surveillance and research to address antimicrobial resistance in human health.

Introducing VIRUS vs. BACTERIA: A Groundbreaking Solution

As the first Clinical Decision Support Software to receive EU-MDR certification in the field of infectious disease management, VIRUS vs. BACTERIA represents a paradigm shift in medical diagnostics. Utilizing only 17 routine blood parameters, along with biological sex and age, this innovative tool distinguishes between viral and bacterial infections with exceptional accuracy. Recently showcased in an article published in Heliyon, VIRUS vs. BACTERIA has demonstrated its efficacy and precision in diagnosis, offering a significant advancement in medical practice.

Inspired by Global Initiatives

The development of VIRUS vs. BACTERIA was inspired by the 2022 G20 Bali summit, which highlighted the urgent need for innovative solutions to combat antimicrobial resistance—a threat often referred to as the silent pandemic. This event galvanized global leaders to address the challenges posed by AMR and emphasized the importance of collaborative efforts in developing effective strategies for infection management.

A Commitment to Excellence

Dr. Marko Notar, CEO of Smart Blood Analytics Swiss, expressed his enthusiasm for achieving EU-MDR certification, emphasizing the company's dedication to advancing healthcare through innovation. By providing clinicians with a precise tool to differentiate between viral and bacterial infections, Smart Blood Analytics Swiss aims to empower healthcare professionals with valuable information, ultimately leading to more effective healthcare practices.

Empowering Healthcare Professionals Worldwide

With its user-friendly interface and powerful capabilities, VIRUS vs. BACTERIA promises to empower healthcare professionals worldwide in their battle against antimicrobial resistance. By expanding the doctor's capacity to differentiate between viral and bacterial infections, this cutting-edge tool facilitates the rational use of antibiotics, thereby mitigating the risk of AMR and improving patient outcomes.